Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 22Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell 10Leukemia 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Neoplasms 4Hodgkin Disease 4Leukemia, Prolymphocytic 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Chromosome 17 deletion 3Burkitt Lymphoma 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Cyclophosphamide 2Busulfan 2simtuzumab 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1ibrutinib 1SCIO-469 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Marrow Diseases × ibrutinib × Clear all
NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡